Anti-PD1/PD-L1 and anti-CTLA-4 therapies were shown to enhance survival in mouse models of LAM (17,18), suggesting that countering immunosuppression in LAM could be an effective strategy for treating LAM. Here, CTLA4 is linked to lymphangioleiomyomatosis.